MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
John O MascarenhasMarina KremyanskayaAndrea PatriarcaFrancesca PalandriTimothy DevosFrancesco PassamontiRaajit K RampalAdam J MeadGabriella HobbsJoseph M ScanduraMoshe TalpazNikki GranacherTim C P SomervailleRonald HoffmanMarielle J WondergemMohamed E SalamaGozde ColakJike CuiJean-Jacques KiladjianAlessandro Maria Maria VannucchiSrdan VerstovsekNatalia Curto-GarcíaClaire N HarrisonVikas K GuptaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The rational combination of the BETi pelabresib and ruxolitinib in JAKi-naïve patients with myelofibrosis was well tolerated and showed durable improvements in spleen and symptom burden, with associated biomarker findings of potential disease-modifying activity.